HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 12, 2015, Pages 3311-3316

  Kiselinova, Maja ^a   Geretti, Anna Maria ^b   Malatinkova, Eva ^a   Vervisch, Karen ^a   Beloukas, Apostolos ^b   Messiaen, Peter ^c   Bonczkowski, Pawel ^a   Trypsteen, Wim ^a   Callens, Steven ^a   Verhofstede, Chris ^d   De Spiegelaere, Ward ^a   Vandekerckhove, Linos ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c JESSA HOSPITAL   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MALE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REPLICATION; BLOOD; COMPARATIVE STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84962348151     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv250     Document Type: Article

References (20)

1. Nicastri E, Palmisano L, Sarmati L et al. HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (,400 HIV-RNA cp/mL) during different antiretroviral regimens. Curr HIV Res 2008; 6: 261-6.
2. Palmer S, Malclarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105: 3879-84.
3. Maldarelli F, Palmer S, King MS et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: 484-8.
4. Doyle T, Smith C, Vitiello P et al. Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 724-32.
5. Fernandez Guerrero ML, Rivas P, Molina M et al. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis 2005; 41: 390-4.
6. Bonora S, Nicastri E, Calcagno A et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81: 400-5.
7. Haim-Boukobza S, Morand-Joubert L, Flandre P et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/mL. AIDS 2011; 25: 341-4.
8. Maggiolo F, Callegaro A, Cologni G et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012; 60: 473-82.
9. Sarmati L, Parisi SG, Montano M et al. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and-RNA levels and CD4 cell gain. J Antimicrob Chemother 2012; 67: 2932-8.
10. Kiselinova M, Pasternak AO, De Spiegelaere W et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. PLoS One 2014; 9: e85999.
11. Strain MC, Lada SM, Luong T et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8: e55943.
12. Palmisano L, Giuliano M, Nicastri E et al. Residual viraemia in subjects with chronic HIV infection and viral load,50 copies/mL: the impact of highly active antiretroviral therapy. AIDS 2005; 19: 1843-7.
13. Rockstroh JK, DeJesus E, Henry K et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62: 483-6.
14. Palmer S, Wiegand AP, Maldarelli F et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531-6.
15. Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 2012; 25: 17-25.
16. Fletcher CV, Staskus K, Wietgrefe SW et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014; 111: 2307-12.
17. Fourati S, Flandre P, Calin R et al. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother 2014; 69: 753-6.
18. Williams JP, Hurst J, Stohr W et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife 2014; 3: e303821.
19. Hocqueloux L, Avettand-Fenoel V, Jacquot S et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68: 1169-78.
20. Buzon MJ, Martin-Gayo E, Pereyra F et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014; 88: 10056-65.